Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636358 | 1.00 | TSHR (0.56) | TSHRDHODHDTYMKAKR1C4AKR1C3 | |
| SCHEMBL27183608 | 0.86 | DHODH (0.49) | TSHRDHODHHPGDALDH1A1TDP1 | |
| SCHEMBL13468191 | 0.86 | DHODH (0.52) | TSHRDHODHHPGDKDM1ARCOR1 | |
| SCHEMBL2043408 | 0.83 | MEN1 (0.50) | DHODHHPGDTDP1 | |
| SCHEMBL1494608 | 0.82 | CYP3A4 (0.52) | TSHRDTYMKAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL6830067 | 0.82 | TSHR (0.59) | TSHRDTYMKHPGDCYP3A4ALDH1A1 | |
| SCHEMBL31218393 | 0.82 | TPMT (0.54) | TSHRDHODHAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL31218394 | 0.82 | TPMT (0.54) | TSHRDHODHAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL19175000 | 0.82 | HKDC1 (0.50) | TSHRDHODHHPGDKDM1ARCOR1 | |
| SCHEMBL28141673 | 0.82 | VCAM1 (0.54) | TSHRDHODHHPGDKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739668-A1 | 1,3-ISOINDOLINEDIONE DERIVATIVES AND HETEROAROMATIC ANALOGUES FOR STIMULATING ENDOTHELIAL CELL-PERICYTE INTERACTION | Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) | 2026-05-13 | — | — | EP | disclosed |
| EP-4596544-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025014359-A1 | 1,3-ISOINDOLINEDIONE DERIVATIVES AND HETEROAROMATIC ANALOGUES FOR STIMULATING ENDOTHELIAL CELL-PERICYTE INTERACTION | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-01-16 | — | — | WO | disclosed |
| CN-117843618-A | EP300/CBP regulator and preparation method and application thereof | 北京沐华生物科技有限责任公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Miracure Biotechnology Limited (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024046504-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| WO-2011130661-A1 | METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MEDIVATION TECHNOLOGIES LLC | 2011-09-29 | — | — | US | disclosed |
| US-8012976-B2 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2011-09-06 | — | — | US | disclosed |
| CN-102171214-A | Dihydropyridophthalazinone inhibitors of poly (ADP-ribose) polymerase (PARP) | BIOMARIN PHARM INC | 2011-08-31 | — | — | CN | disclosed |
| EP-2326650-A2 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | BioMarin Pharmaceutical Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010017055-A2 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109868-A1 | EP300/CBP MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | EP300, CREBBP, BPTF | TSHR 4008/4885DHODH 4487/4885DTYMK 2583/4885 |
| US-20110237581-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | TSHR 3935/4885DHODH 796/4885DTYMK 355/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | TSHR 3819/4885DHODH 619/4885DTYMK 3111/4885 |
| US-20100035883-A1 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | TSHR 3935/4885DHODH 796/4885DTYMK 355/4885 |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | TSHR 4393/4885DHODH 815/4885DTYMK 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.